Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
54,731,500
-
Total 13F shares
-
29,540,857
-
Share change
-
-11,810,221
-
Total reported value
-
$15,803,442
-
Put/Call ratio
-
4.6%
-
Price per share
-
$0.54
-
Number of holders
-
50
-
Value change
-
-$30,404,718
-
Number of buys
-
20
-
Number of sells
-
50
Institutional Holders of Marinus Pharmaceuticals, Inc. - Common Stock (MRNS) as of Q4 2024
As of 31 Dec 2024,
Marinus Pharmaceuticals, Inc. - Common Stock (MRNS) was held by
50 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
29,540,857 shares.
The largest 10 holders included
Beryl Capital Management LLC, MORGAN STANLEY, ODDO BHF ASSET MANAGEMENT SAS, Bain Capital Life Sciences Investors, LLC, abrdn plc, VANGUARD GROUP INC, Woodline Partners LP, GSA CAPITAL PARTNERS LLP, TANG CAPITAL MANAGEMENT LLC, and BlackRock, Inc..
This page lists
51
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.